Skip to main content

Find Clinical Trials

Home
Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma

Clinical trial condition

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma

Explore clinical trials studying B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma trial results

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT02950220

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details